
Kadmon Corporation LLC Profile last edited on: 12/3/2023
CAGE: 6ALL0
UEI: EZRWFE9KAEF6
Business Identifier: Therapeutic drugs for the treatment of oncology, immunology and infectious or neurodegenerative diseases Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
450 East 29th Street 5th Floor
New York, NY 10016
New York, NY 10016
(212) 308-6000 |
medicalinformation@kadmon.com |
www.kadmon.com |
Location: Single
Congr. District: 12
County: New York
Congr. District: 12
County: New York
Public Profile
Kadmon Holdings, Inc.,(NYSE:KDMN) is a biopharmaceutical company working in small molecules and biologics space for application in autoimmune and fibrotic, oncology, and genetic diseases. The company offers a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases. The firm's lead product candidates include KD025, a rho-associated coiled-coil kinase2 inhibitor, which is in Phase II clinical studies for the treatment of autoimmune, fibrotic, and neurodegenerative diseases; Tesevatinib, an oral tyrosine kinase inhibitor that is in Phase II clinical studies for use in the treatment of non-small cell lung cancer and glioblastoma, as well as for treating autosomal dominant polycystic kidney disease; and KD034 that is used for the treatment of Wilson's disease, a genetic liver disease. Kadmon Holdings, Inc. has a strategic collaborations and license agreements with a wide range of entities foreign and domestic
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
150-249Revenue Range
15M-20MVC funded?
YesPublic/Private
Publicly TradedStock Info
NYSE : KDMNIP Holdings
25-49Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2014 | 1 | NIH | $172,052 | |
Project Title: Discovery of Inhibitors of the Metabolic Oncogene 3-Phosphoglycerate Dehydrogenas | ||||
2012 | 1 | NIH | $184,624 | |
Project Title: Treatment Of Cytomegalovirus By Inhibition Of Host Lipid Synthesis |
Key People / Management
Samuel D Waksal -- Founder, Chairman and CEO
Bryson D Bennett
Lawrence Cohen -- Senior Vice President, Business Development
Michael J Howerton -- Chief Operating Officer, Chief Financial Officer & Executive Vice President
Peter Mills
Kellen Leonard Olszewski
John Ryan -- Chief Medical Officer & Executive Vice President
Adriann Sax -- Executive Vice President, Chief Commercial Officer
Bryson D Bennett
Lawrence Cohen -- Senior Vice President, Business Development
Michael J Howerton -- Chief Operating Officer, Chief Financial Officer & Executive Vice President
Peter Mills
Kellen Leonard Olszewski
John Ryan -- Chief Medical Officer & Executive Vice President
Adriann Sax -- Executive Vice President, Chief Commercial Officer